Hemedah M, Mitchelson F J, Coupar I M
Department of Pharmaceutical Biology and Pharmacology, Victorian College of Pharmacy, Monash University (Parkville Campus), Australia.
Life Sci. 1998;63(15):1371-6. doi: 10.1016/s0024-3205(98)00401-9.
Activation of histamine H3 receptors by histamine (0.1 to 10 microM), (R)alpha-methylhistamine and N(alpha)-methylhistamine (0.01 to 0.3 microM) was shown to inhibit cholinergic nerve transmission in the guinea-pig ileum. Iodoaminopotentidine (IAP 300 nM), a potent H2 receptor antagonist, was found to decrease this effect but had no significant effect (P>0.05) on contractile responses produced by exogenous acetylcholine (0.2 microM). Dimaprit (0.1 to 10 microM) an H2 receptor agonist/H3 receptor antagonist, produced no significant effect (P>0.05) on the response to cholinergic nerve stimulation but reduced the effect of N(alpha)-methylhistamine. Furthermore, ranitidine (10 microM) an H2 receptor antagonist did not modify the inhibitory effect of histamine. These results suggest that IAP may inhibit H3 receptors in the ileum at similar concentrations reported to inhibit H2 receptors in functional studies.
组胺(0.1至10微摩尔)、(R)α-甲基组胺和N(α)-甲基组胺(0.01至0.3微摩尔)对组胺H3受体的激活被证明可抑制豚鼠回肠中的胆碱能神经传递。强力H2受体拮抗剂碘胺泊替定(IAP,300纳摩尔)被发现可降低这种效应,但对外源性乙酰胆碱(0.2微摩尔)产生的收缩反应无显著影响(P>0.05)。H2受体激动剂/H3受体拮抗剂二甲双胍(0.1至10微摩尔)对胆碱能神经刺激的反应无显著影响(P>0.05),但可降低N(α)-甲基组胺的效应。此外,H2受体拮抗剂雷尼替丁(10微摩尔)并未改变组胺的抑制作用。这些结果表明,IAP可能在与功能研究中报道的抑制H2受体相似的浓度下抑制回肠中的H3受体。